(Stroke. 1996;27:1393-1398.)
© 1996 American Heart Association, Inc.
Articles |
Cerebroprotective Effects of Aminoguanidine in a Rodent Model of Stroke
the Laboratory of Biomedical Science, The Picower Institute for Medical Research (K.M.C., M.M., G.A.Z., O.B., A.C., K.J.T.), and the Department of Surgery (Neurosurgery), North Shore University Hospital (D.R., K.J.T.), Manhasset, NY; and the Division of Neurosurgery, The New York Hospital—Cornell Medical Center, New York, NY (K.M.Z., G.A.Z., K.J.T.).
Correspondence to Kevin J. Tracey, Laboratory of Biomedical Science, Picower Institute for Medical Research, 350 Community Dr, Manhasset, NY 11030. E-mail ktracey@picower.edu.
Background and Purpose During a cerebral infarction, a complex cascade of cytotoxic events ultimately determines the volume of brain cell loss. The studies presented here demonstrate that aminoguanidine, an experimental therapeutic currently in clinical trials to prevent diabetic complications, is cerebroprotective in focal cerebral infarction.
Methods Adult Lewis rats (n=6 to 12 per group) were anesthetized with ketamine and subjected to focal cerebral infarction by tandem permanent occlusion of the right middle cerebral artery and ipsilateral common carotid artery (CCA), followed by temporary occlusion of the contralateral CCA. Infarct volume (cortical) was assessed 24 hours after the onset of ischemia by planimetric analysis of coronal brain slices stained with tetrazolium.
Results Aminoguanidine (320 mg/kg IP) administered 15 minutes after the onset of ischemia resulted in a significant reduction of infarct volume (7.6±2.6% of hemisphere in controls versus 1.3±0.2% of hemisphere in aminoguanidine-treated rats; P<.05). Administration of aminoguanidine conferred significant cerebroprotection even when administered 1 or 2 hours after the onset of ischemia (88% and 85% reduction from control, respectively; P<.05). Cerebroprotection by aminoguanidine was independent of systemic physiological variables known to influence stroke size (eg, temperature, mean arterial blood pressure, blood glucose, and arterial pH, PCO2, and PO2).
Conclusions These results indicate that the stroke-reducing properties of aminoguanidine are dose and time dependent, with substantial cerebroprotection persisting even with drug delivery up to 2 hours after the onset of ischemia. It is now plausible to pursue development of aminoguanidine as an experimental therapeutic in stroke, and possible mechanisms of these cerebroprotective effects are under consideration.
Editorial Comment
Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pa
This article has been cited by other articles:
 |
|
 |
|
  G. Iohom, S. Szarvas, V. Larney, J. O'Brien, E. Buckley, M. Butler, and G. Shorten Perioperative Plasma Concentrations of Stable Nitric Oxide Products Are Predictive of Cognitive Dysfunction After Laparoscopic Cholecystectomy Anesth. Analg., October 1, 2004; 99(4): 1245 - 1252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Tian, A. W. Gannon, R. A. Khalil, and R. D. Manning Jr. Mechanisms of salt-sensitive hypertension: role of renal medullary inducible nitric oxide synthase Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2003; 284(2): R372 - R379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. Han, Y. Qiao, M. Karabiyikoglu, R. G. Giffard, and M. A. Yenari Influence of Mild Hypothermia on Inducible Nitric Oxide Synthase Expression and Reactive Nitrogen Production in Experimental Stroke and Inflammation J. Neurosci., May 15, 2002; 22(10): 3921 - 3928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ivanova, F. Batliwalla, J. Mocco, S. Kiss, J. Huang, W. Mack, A. Coon, J. W. Eaton, Y. Al-Abed, P. K. Gregersen, et al. Neuroprotection in cerebral ischemia by neutralization of 3-aminopropanal PNAS, April 16, 2002; 99(8): 5579 - 5584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Sell, J. F. Nelson, and V. M. Monnier Effect of Chronic Aminoguanidine Treatment on Age-Related Glycation, Glycoxidation, and Collagen Cross-linking in the Fischer 344 Rat J. Gerontol. A Biol. Sci. Med. Sci., September 1, 2001; 56(9): B405 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Y. Tan, S. Meng, G. W. Cason, and R. D. Manning Jr. Mechanisms of salt-sensitive hypertension: role of inducible nitric oxide synthase Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2000; 279(6): R2297 - R2303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fisher and W. Schaebitz An Overview of Acute Stroke Therapy: Past, Present, and Future Arch Intern Med, November 27, 2000; 160(21): 3196 - 3206. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Castillo, R. Rama, and A. Davalos Nitric Oxide-Related Brain Damage in Acute Ischemic Stroke Stroke, April 1, 2000; 31(4): 852 - 857. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lipton Ischemic Cell Death in Brain Neurons Physiol Rev, October 1, 1999; 79(4): 1431 - 1568. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. O'MAHONY and M. J KENDALL Nitric oxide in acute ischaemic stroke: a target for neuroprotection J. Neurol. Neurosurg. Psychiatry, July 1, 1999; 67(1): 1 - 3. [Full Text]
|
|
|
|
 |
|
 S. Ivanova, G. I. Botchkina, Y. Al-Abed, M. Meistrell III, F. Batliwalla, J. M. Dubinsky, C. Iadecola, H. Wang, P. K. Gregersen, J. W. Eaton, et al. Cerebral Ischemia Enhances Polyamine Oxidation: Identification of Enzymatically Formed 3-Aminopropanal as an Endogenous Mediator of Neuronal and Glial Cell Death J. Exp. Med., July 20, 1998; 188(2): 327 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ivanova, F. Batliwalla, J. Mocco, S. Kiss, J. Huang, W. Mack, A. Coon, J. W. Eaton, Y. Al-Abed, P. K. Gregersen, et al. Neuroprotection in cerebral ischemia by neutralization of 3-aminopropanal PNAS, April 16, 2002; 99(8): 5579 - 5584. [Abstract] [Full Text] [PDF]
|
|